搜索结果

Search Results for " inhibitor of mcl1 "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T12041	MIM1 Inhibitor of Mcl-1	BCL	Apoptosis
	MIM1 (Inhibitor of Mcl-1) 是一种骨髓细胞因子 1 抑制剂。
T9083	TC11 CLT-003,1H-Isoindole-1,3(2H)-dione, 5-amino-2-[2,6-bis(1-methylethyl)phenyl]-TC11	BCL; Caspase; CDK	Apoptosis; Cell Cycle/Checkpoint; Proteases/Proteasome
	TC11 (1H-Isoindole-1,3(2H)-dione, 5-amino-2-[2,6-bis(1-methylethyl)phenyl]-TC11) 是一种有效的肿瘤细胞增殖抑制剂，并通过激活 caspase-3、8 和 9 诱导细胞凋亡。在长时间有丝分裂阻滞期间，它诱导 MCL1降解导致凋亡。它作为苯酞酰亚胺衍生物在结构上与免疫调节药物相关。
T11976	Mcl1-IN-4	Others	Others
	Mcl1-IN-4 is an inhibitor of Mcl1 ( IC50:0.2 μM).
T16029	Mcl1-IN-3	Others	Others
	Mcl1-IN-3 is an Mcl1 inhibitor. It has an IC50 and Ki of 0.67 and 0.13 μM, respectively.
T11973	Mcl1-IN-11	BCL	Apoptosis
	Mcl1-IN-11 (Compound G) is a selective Mcl-1 inhibitor, less potent at Bcl-2, with Kis of 0.06 and 4.2 μM, respectively.
T11975	PROTAC Mcl1 degrader-1	BCL	Apoptosis
	PROTAC Mcl1 degrader-1 induces the ubiquitination and proteasomal degradation of Mcl-1 by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1 inhibitor S1-6 with μM-range affinity. PROTAC Mcl1 degrader-1, a proteolysis targeting chimera (PROTAC), is a potently and selectively Mcl-1 inhibitor with an IC50 of 0.78 μM.
T11977	Mcl1-IN-9	BCL	Apoptosis
	Mcl1-IN-9 is a potent myeloid cell leukemia-1 (Mcl-1) Inhibitor with an IC50 of 446 nM in reengineered BCR-ABL+ B-ALL cells and a Ki of 0.03 nM.
T11974	Mcl1-IN-12	BCL	Apoptosis
	Mcl1-IN-12 has anti-tumor activity.It is a selective Mcl-1 inhibitor, less potent at Bcl-2, with Kis of 0.29 and 3.1 μM, respectively.
T71242	AZD-1897
	AZD-1897 is an ATP-competitive pan-PIM inhibitor. When combined with the Akt inhibitor AZD5363, AML cells from putative leukaemia stem cells incur a reduction in levels of the anti-apoptotic protein MCL1. The combination of PIM and Akt inhibition holds promise for the treatment of AML.
T70953	AZ5576 racemate
	AZ5576 racemate is a racemic mixture of AZ5576 isomers. AZ5576 is a potent, highly selective, and orally bioavailable inhibitor of Cdk9 that inhibits Cdk9 enzyme activity with an IC50 <5nM and decreases phosphorlyation of Ser2-RNAPII in cells with an IC50 of 96nM. In the MLL-fusion containing acute myeloid leukemia (AML) line, MV411, short-term treatment with AZ5576 led to a rapid dose-dependent decrease in pSer2-RNAPII with concomitant loss of Mcl1 mRNA and protein, resulting in the cleavage a...